[go: up one dir, main page]

MX2018014718A - Compuestos y su uso para reducir los niveles de ácido úrico. - Google Patents

Compuestos y su uso para reducir los niveles de ácido úrico.

Info

Publication number
MX2018014718A
MX2018014718A MX2018014718A MX2018014718A MX2018014718A MX 2018014718 A MX2018014718 A MX 2018014718A MX 2018014718 A MX2018014718 A MX 2018014718A MX 2018014718 A MX2018014718 A MX 2018014718A MX 2018014718 A MX2018014718 A MX 2018014718A
Authority
MX
Mexico
Prior art keywords
uric acid
compounds
reduce
levels
serum
Prior art date
Application number
MX2018014718A
Other languages
English (en)
Other versions
MX375222B (es
Inventor
J Piwinski John
Larivée Alexandre
Siddiqui Arshad
THAI Karen
P Jr Warrell Raymond
Original Assignee
Acquist Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acquist Llc filed Critical Acquist Llc
Publication of MX2018014718A publication Critical patent/MX2018014718A/es
Publication of MX375222B publication Critical patent/MX375222B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos bifuncionales que aumentan la excrecion de acido urico y reducen la produccion de acido urico, y compuestos monofuncionales que aumentan la excrecion de acido urico o reducen la produccion de acido urico. Tambien se proporcionan metodos de uso de estos compuestos para reducir los niveles de acido urico en sangre o suero, para tratar trastornos asociados al exceso de acido urico y para mantener los niveles normales de acido urico en sangre o suero, o en todo el cuerpo. Tambien se proporcionan composiciones farmaceuticas que comprenden los compuestos bifuncionales y monofuncionales.
MX2018014718A 2016-07-06 2017-07-06 Compuestos y su uso para reducir los niveles de ácido úrico MX375222B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662358669P 2016-07-06 2016-07-06
PCT/US2017/040836 WO2018009615A1 (en) 2016-07-06 2017-07-06 Compounds and their use for reducing uric acid levels

Publications (2)

Publication Number Publication Date
MX2018014718A true MX2018014718A (es) 2019-04-11
MX375222B MX375222B (es) 2025-03-06

Family

ID=60913101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014718A MX375222B (es) 2016-07-06 2017-07-06 Compuestos y su uso para reducir los niveles de ácido úrico

Country Status (13)

Country Link
US (3) US10688095B2 (es)
EP (1) EP3481819B1 (es)
JP (1) JP7006960B2 (es)
KR (1) KR102444538B1 (es)
CN (1) CN109476642B (es)
BR (1) BR112019000201A2 (es)
CA (1) CA3029883A1 (es)
DK (1) DK3481819T3 (es)
ES (1) ES2925186T3 (es)
MX (1) MX375222B (es)
PT (1) PT3481819T (es)
TW (1) TWI749024B (es)
WO (1) WO2018009615A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI772309B (zh) * 2016-06-30 2022-08-01 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途(二)
WO2018009615A1 (en) * 2016-07-06 2018-01-11 Acquist Llc Compounds and their use for reducing uric acid levels
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
CR20200054A (es) * 2017-08-09 2020-03-21 Denali Therapeutics Inc Compuestos, composiciones y métodos
PT3676297T (pt) 2017-09-01 2023-08-29 Denali Therapeutics Inc Compostos, composições e métodos
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
TWI877136B (zh) 2019-02-13 2025-03-21 美商戴納立製藥公司 化合物、組合物及方法
TW202136237A (zh) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
CN114989087B (zh) * 2021-03-01 2024-08-16 中国科学院上海有机化学研究所 一种含氟羟基喹啉类化合物的合成方法
TWI800315B (zh) * 2022-03-21 2023-04-21 銓安智慧科技股份有限公司 資料檔案傳輸以及取用權限管理系統與方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3944667A (en) 1972-09-08 1976-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Formylazapentadienenitriles
DE2832698A1 (de) 1978-07-26 1980-02-07 Bayer Ag Substituierte 5-phenylcarbamoyl- barbitursaeuren, verfahren zu ihrer herstellung und ihre verwendung als insektizide
US4879276A (en) * 1983-12-19 1989-11-07 Uniroyal Chemical Ltd./Uniroyal Chemical Ltee Method for reducing serum uric acid levels
IL73840A (en) 1983-12-19 1988-11-15 Uniroyal Chem Co Inc 2-thio-5-(thio)carbamoyl barbituric acid derivatives,their preparation and pharmaceutical compositions containing them
ZA849819B (en) * 1983-12-19 1985-07-31 Uniroyal Inc 5-pyrimidinecarboxamides and thiocarboxamides and treatment of leukemia and tumors therewith
CH657015A5 (de) 1984-06-27 1986-08-15 Ciba Geigy Ag Motten- und kaeferschutzmittel.
PH24423A (en) 1985-02-15 1990-06-25 Ciba Geigy Ag 5-(azolyloxyphenylcarbamoyl)barbituric acid derivatives as anthelmintics
US4636508A (en) 1985-04-22 1987-01-13 Uniroyal Chemical Company, Inc. 5-pyrimidinecarboxyamides and treatment of leukemia therewith
US4880811A (en) 1987-06-24 1989-11-14 Memorial Hospital For Cancer And Allied Diseases Use of C-5 mono-substituted barbiturates to treat disorders of uric acid metabolism
AU7540991A (en) * 1990-03-09 1991-10-10 Memorial Hospital For Cancer And Allied Diseases C-5 mono-substituted barbiturates in combination with therapeutic agents and uses thereof
JP2002504916A (ja) 1997-06-21 2002-02-12 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
JP2011518216A (ja) 2008-04-22 2011-06-23 アストラゼネカ アクチボラグ 置換ピリミジン−５−カルボキサミド
US9428466B2 (en) * 2013-11-13 2016-08-30 Raymond P. Warrell, Jr. Methods for reducing uric acid levels using barbiturate derivatives
EP3104861A4 (en) * 2014-02-14 2017-10-04 Warrell, Raymond P., Jr. Bifunctional compounds and use for reducing uric acid levels
KR20170103803A (ko) * 2015-01-22 2017-09-13 주니어 워렐 레이먼드 피. 요산 수준의 저감을 위한 이작용성 화합물 및 용도
TWI772309B (zh) * 2016-06-30 2022-08-01 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途(二)
WO2018009615A1 (en) * 2016-07-06 2018-01-11 Acquist Llc Compounds and their use for reducing uric acid levels

Also Published As

Publication number Publication date
CN109476642A (zh) 2019-03-15
MX375222B (es) 2025-03-06
EP3481819B1 (en) 2022-06-01
CN109476642B (zh) 2022-01-25
DK3481819T3 (da) 2022-07-25
EP3481819A4 (en) 2020-02-19
US20200197393A9 (en) 2020-06-25
ES2925186T3 (es) 2022-10-14
US20190117654A1 (en) 2019-04-25
CA3029883A1 (en) 2018-01-11
US20200268757A1 (en) 2020-08-27
TW201805282A (zh) 2018-02-16
JP2019520387A (ja) 2019-07-18
KR102444538B1 (ko) 2022-09-16
BR112019000201A2 (pt) 2019-07-09
WO2018009615A9 (en) 2018-06-28
JP7006960B2 (ja) 2022-01-24
KR20190025612A (ko) 2019-03-11
US20210236495A1 (en) 2021-08-05
WO2018009615A1 (en) 2018-01-11
PT3481819T (pt) 2022-08-12
US11020397B2 (en) 2021-06-01
TWI749024B (zh) 2021-12-11
EP3481819A1 (en) 2019-05-15
US10688095B2 (en) 2020-06-23

Similar Documents

Publication Publication Date Title
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
MX388013B (es) Compuestos y usos de estos para la modulación de la hemoglobina.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX379228B (es) Compuestos y usos de estos para la modulación de la hemoglobina.
MX2015011448A (es) Compuestos y sus usos para modular la hemoglobina.
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CR20180200A (es) Ciano tienotriazolpirazinas y usos de las mismas
UY35747A (es) Derivados sustituidos de fenilalanina
ECSP17010482A (es) Novedosas pirimidinas 2,5-sustituidas
CR20160133A (es) Derivados de fenilalanina sustituidos
EA202090270A1 (ru) Новые замещенные производные ксантина
UY35745A (es) Derivados sustituidos de fenilalanina

Legal Events

Date Code Title Description
FG Grant or registration